Skip to main content
Premium Trial:

Request an Annual Quote

Proteome Sciences Inks Deal with Eisai for First Commercial Use of Alzheimer's Biomarker Panel


Proteome Sciences said this week it has contracted with pharmaceutical firm Eisai to measure protein biomarkers tied to Alzheimer's disease.

The agreement calls for Proteome Sciences to quantify in an undisclosed number of human samples levels of the nine proteins in its AD-TMT-SRM assay, which it introduced this summer. This is the first commercial contract the company has signed for use of the assay, chief operating officer Ian Pike told ProteoMonitor.

The assay uses multiple-reaction-monitoring mass spectrometry and Proteome Science's proprietary Tandem Mass Tag technology to measure the proteins of interest in plasma. The nine biomarkers in the Alzheimer's panel include known biomarkers for the disease like ApoE and clusterin, as well as new markers like gelsolin, alpha-2-macroglobulin, and complement factor H.

Pike declined to say to what uses Eisai would be putting the company's biomarker data, but in a July 2010 interview with ProteoMonitor he noted that some of the nine proteins in the panel were expected to be "very helpful in early detection of [Alzheimer's] in the prodromal phase" while others would "be useful in predicting how the disease is going to progress" (PM 07/16/2010).

Financial and other terms of the deal were not disclosed.